Cargando…
Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
BACKGROUND: Paliperidone (9-hydroxyrisperidone), the major active metabolite of risperidone, has been introduced as a novel atypical antipsychotic agent in many countries. It is available both as an oral extended-release (ER) formulation and as a long-acting injection (paliperidone palmitate, PP), w...
Autores principales: | Zhang, LiLi, Li, JiTao, Zhao, YanJie, Su, Yun’Ai, Si, Tianmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714741/ https://www.ncbi.nlm.nih.gov/pubmed/26811684 http://dx.doi.org/10.2147/NDT.S64672 |
Ejemplares similares
-
Dose-Dependent Efficacy of Aripiprazole in Treating Patients With Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Qian, Li, et al.
Publicado: (2021) -
Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si, Tianmei, et al.
Publicado: (2019) -
Postnatal BDNF Expression Profiles in Prefrontal Cortex and Hippocampus of a Rat Schizophrenia Model Induced by MK-801 Administration
por: Guo, Chunmei, et al.
Publicado: (2010) -
Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
por: Li, Nan, et al.
Publicado: (2018) -
Dose Adjustment Model of Paliperidone in Patients With Acute Schizophrenia: A post hoc Analysis of an Open-Label, Single-Arm Multicenter Study
por: Si, Tianmei, et al.
Publicado: (2021)